ArticleJournal of biological engineering2026
Engineering of Corynebacterium glutamicum for biosynthesis of the pharmaceutically active N-acetyltyramine: establishing and optimizing de novo production.
Article in Journal of biological engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundN-Acetyltyramine is increasingly recognized for its diverse pharmaceutically relevant properties. In particular, it exhibits antimicrobial activity against multi-drug resistant pathogens, which pose a considerable health challenge. Therefore, the demand for a sustainable and efficient N-acetyltyramine production arises.
resultsHere, we engineered Corynebacterium glutamicum for de novo production of N-acetyltyramine. Heterologous overexpression of different bacterial and insect acetyltransferase genes in a tyramine overproducing strain identified the arylalkylamine N-acetyltransferase from Bombyx mori as the most promising enzyme, resulting in an N-acetyltyramine titer of 5.5 ± 0.3 mM. Design of Experiment-based optimization of the culture medium revealed urea and L-phenylalanine as media components significantly affecting N-acetyltyramine production. Combining media optimization with genetic engineering to balance the expression strength of the genes encoding the L-tyrosine decarboxylase from Levilactobacillus brevis and the arylalkylamine N-acetyltransferase from B. mori increased de novo N-acetyltyramine production to 13.8 ± 0.1 mM (2.5 ± 0.1 g/L). The optimized medium composition was also transferable to the production of other L-tyrosine derivatives, tyramine and tyrosol, increasing their titers by 24% and 44%, respectively. In addition, supplementing the established N-acetyltyramine producing strain with propionate as a second carbon source enabled the production of N-propionyltyramine. To the best of our knowledge, this represents the first report describing biotechnological production of N-propionyltyramine.
conclusionIn this study, de novo N-acetyltyramine production was established and substantially increased through the combined implementation of metabolic engineering and media optimization strategies. The successful transfer of the optimized medium to enhance the production of additional L-tyrosine derivatives underscores the potential of integrating genetic engineering with culture media refinement to improve biotechnological processes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.